06/22/22 7:03 AMNasdaq : MRNA Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5Moderna, Inc., (NASDAQ:MRNA) a biotechnology companyRHEA-AIneutral
06/21/22 7:05 PMNasdaq : MRNA Moderna Announces Plan to Bring mRNA Innovation to the United KingdomManufacturing facility would provide access to domestically manufactured vaccines against respiratory viruses Moderna would expand its presence in the UK through investments in R&D activities and capabilities Collaboration would support the UK with direct access to rapid pandemic responseRHEA-AIneutral
06/17/22 9:05 AMNasdaq : MRNA covid-19Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and OldermRNA-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given one month apart mRNA-1273 has been administered to millions of children and adolescents over the age of 6 worldwide, with safety and tolerability profiles consistent withRHEA-AIpositive
06/08/22 7:00 AMNasdaq : MRNA Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against OmicronData Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant mRNA-1273.214 Exhibited an 8-Fold Boost in Neutralizing Geometric Mean Titers Against Omicron Among Baseline Seronegative Participants Safety and Tolerability ProfileRHEA-AInegative
06/07/22 7:00 AMNasdaq : MRNA clinical trialModerna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)mRNA-1010 is Moderna's first seasonal influenza vaccine candidate to enter a Phase 3 trial mRNA-1010 is one of several influenza vaccine candidates being developed in Moderna's respiratory portfolio Moderna now has four programs in Phase 3 studies: Omicron-containing bivalent COVID booster,RHEA-AIneutral
06/02/22 6:30 AMNasdaq : MRNA covid-19Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply AgreementModerna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the European Commission (EC) to amend their originally agreed contractual delivery schedules for the ModernaRHEA-AIneutral
06/01/22 7:57 AMNasdaq : MRNA conferencesModerna to Present at Upcoming Conferences in June 2022Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences: 2022 Jefferies Healthcare Conference on Wednesday, June 8 thRHEA-AIneutral
05/31/22 3:56 AMNYSE, Nasdaq : TAK, MRNA covid-19Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to ModernaModerna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and Takeda announced to transfer...RHEA-AIvery positive
05/31/22 3:40 AMNasdaq, NYSE : MRNA, TAK covid-19Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to ModernaModerna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for Spikevax TM from August 1, 2022 Companies concluded memorandum of understanding that Takeda will continue to provideRHEA-AIvery positive
05/18/22 3:55 PMNasdaq : MRNA conferencesModerna to Present at the UBS 2022 Global Healthcare ConferenceModerna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the UBS 2022 Global Healthcare Conference on Tuesday, May 24 th at 9:15 a.m. ET. A liveRHEA-AIneutral